BI opens up data files

Share this article:

Boehringer Ingelheim announced Monday that it will make clinical study data accessible once a drug has been approved or a drug development program has been terminated.

The company said in a statement Monday that researchers will be able to request de-identified patient data and will receive information if an independent third-party review panel approves the study proposal. BI will redact the information.

The data repository will go back to 1998.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.